

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/899,429	07/03/2001	Rudolf Hauptmann	98,385-J	7549
20306	7590 10/04/2004		EXAMINER	
MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP			O HARA, EILEEN B	
300 S. WACE			ART UNIT	PAPER NUMBER
32ND FLOOR			AKI UNI	TATER NOMBER
CHICAGO, 1	IL 60606	1646		
			DATE MAILED: 10/04/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

1 245						
	Application No.	Applicant(s)				
	09/899,429	HAUPTMANN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Eileen O'Hara	1646				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the	ne correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1. after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period of the period for reply within the set or extended period for reply will, by statute any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply by within the statutory minimum of thirty (30) will apply and will expire SIX (6) MONTHS to cause the application to become ABAND	be timely filed) days will be considered timely. from the mailing date of this communication. ONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 09 Ju	<u>ıly 2004</u> .					
2a) ☐ This action is FINAL . 2b) ☑ This	action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11	, 453 O.G. 213.				
Disposition of Claims						
 4) Claim(s) 1,23,41,42,45-48 and 50-59 is/are pe 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 1,23,41,42,45-48 and 50-59 is/are rej 7) Claim(s) is/are objected to. 	wn from consideration.					
8) Claim(s) are subject to restriction and/o	r election requirement.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	epted or b) objected to by the drawing(s) be held in abeyance. tion is required if the drawing(s) is	See 37 CFR 1.85(a). s objected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Application in Appli	cation No. <u>07511,430</u> . eived in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summ					
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 	Paper No(s)/Ma 5) Notice of Inform 6) Other:	nal Patent Application (PTO-152)				

Art Unit: 1646

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application. This application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid. Applicant's submission filed on July 9, 2004 has been entered.

Claims Status

2. Claims 1, 23, 41, 42, 45-48 and 50-59 are pending in the instant application. Claims 1, 23, 45, 50 and 51 have been amended and claims 2-22, 24-40, 43-44 and 49 have been canceled as requested by Applicant in the Paper filed July 9, 2004.

Withdrawn Objections and Rejections

3. Any objection or rejection of record which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.

Double Patenting

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The

Art Unit: 1646

filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 1, 23, 41, 45-48 and 50-59 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1, 23, 41, 45-48 and 54-62 of copending Application No. 09/898,234. This is a provisional double patenting rejection since the conflicting claims have not in fact been patented. The claims are considered to be identical in scope because the only difference between the claims is the recitation in the instant application that the polypeptide is not associated with human urinary proteins, but since the polypeptide is recombinantly produced, it would not be associated with urinary proteins, and this limitation therefore has no meaning and is not given weight.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4.2 Claim 42 remains provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 42 and 51-53 of U.S. Patent Application No. 09/898,234 for reasons of record in the previous office action, Paper No. 17, at pages 2-3.

Art Unit: 1646

4.3 Claims 1, 23, 41, 42, 45-48 and 50-59 remain rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-44 of U.S. Patent No. 6,417,158, for reasons of record in the previous Office Action, Paper No. 18, at pages 2-3.

On page 5 of the response, Applicants acknowledge the rejections under the judicially created doctrine of obviousness-type double patenting and elect to address these grounds of rejection by submitting a Terminal Disclaimer or by argument upon notification that all other conditions for patentability have been met and the claims are otherwise in condition for allowance.

All other rejections have been withdrawn in response to Applicants' amendment, so with the exception of these rejections, the claims are otherwise allowable.

It is believed that all pertinent arguments have been answered.

Conclusion

5. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eileen B. O'Hara, whose telephone number is (571) 272-0878. The examiner can normally be reached on Monday through Friday from 10:00 AM to 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached at (571) 272-0961.

Art Unit: 1646

Page 5

The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal/pair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll free). Clear B.O Hava

Eileen B. O'Hara, Ph.D.

Patent Examiner

PATENT EXAMINER